TerminatedPhase 2

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Stopped: The data did not support study endpoints for acute cough, based on an interim efficacy analysis; not due to safety concerns.

United Kingdom46 participantsStarted 2018-07-04

Plain-language summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in adult participants with induced viral upper respiratory tract infections (URTI).

Who can participate

Age range

18 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * In good general health * Susceptible to human rhinovirus type 16 (HRV-16) * Male or non-pregnant and non-breast feeding female * If female of reproductive potential, agrees to use 1 form of acceptable birth control Exclusion Criteria: * Donated blood within 56 days or donated plasma within 7 days prior to dosing * History of significant multiple and/or severe allergies * Recent history of respiratory tract infection * History of cancer * Body mass index \<18 kg/m\^2 or ≥40 kg/m\^2 * History of major surgery or loss of 1 unit of blood * History of allergic reaction to sulfonamides * Received medications within 14 days prior to randomization * Significantly abnormal laboratory tests at Screening * Current smoker, smoked within 5 years of Screening, or significant past smoking history * History of alcohol or drug abuse

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Awake Coughs Per Hour on Day 3

Timeframe: Day 3

Trial details

NCT IDNCT03569033

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-10-31

Results submitted2019-10-28

View on ClinicalTrials.gov More Acute Cough trials

Who can participate

Age range

18 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.